Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Nutt

Showing results (131-140 of 389) with videos related to

Pageof 39
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 4, 2012
The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteersInnar Tõru, Eduard Maron, Mait Raag, et al.
Journal of Psychopharmacology (Oxford, England)|October 28, 2025
A long, strange trip: Ketamine treatment in psychiatryDavid J Nutt, Celia Morgan, David Erritzoe, et al.
Frontiers in Human Neuroscience|June 7, 2014
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteersLeor Roseman, Robert Leech, Amanda Feilding, et al.
Journal of Psychopharmacology (Oxford, England)|May 1, 2023
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depressionBrandon Weiss, David Erritzoe, Bruna Giribaldi, et al.
Acta Poloniae Pharmaceutica|April 6, 2006
Preparation, structure and affinity for imidazoline I2 receptors and alpha2-adrenoceptors of 1-[(4,5-dihydroimidazolidin-2-yl)imino]indan-2-olsAnita Kornicka, Franciszek Saczewski, Robin J Tyacke, et al.
Journal of Psychopharmacology (Oxford, England)|March 15, 2006
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteersJayne E Bailey, Adrian Kendrick, Alison Diaper, et al.
Journal of Psychopharmacology (Oxford, England)|February 2, 2022
Adverse effects of psychedelics: From anecdotes and misinformation to systematic scienceAnne K Schlag, Jacob Aday, Iram Salam, et al.
Psychopharmacology|January 17, 2007
A translational, caffeine-induced model of onset insomnia in rats and healthy volunteersLouise M Paterson, Sue J Wilson, David J Nutt, et al.
Psychiatry Research|May 22, 2003
Increased sympathetic response to standing in panic disorderNick J Coupland, Susan J Wilson, John P Potokar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 19, 2013
A translational rodent assay of affective biases in depression and antidepressant therapySarah A Stuart, Paul Butler, Marcus R Munafò, et al.
Pageof 39

Showing results (131-140 of 389) with videos related to

Sort By:
Pageof 39
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 4, 2012
The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteersInnar Tõru, Eduard Maron, Mait Raag, et al.
Journal of Psychopharmacology (Oxford, England)|October 28, 2025
A long, strange trip: Ketamine treatment in psychiatryDavid J Nutt, Celia Morgan, David Erritzoe, et al.
Frontiers in Human Neuroscience|June 7, 2014
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteersLeor Roseman, Robert Leech, Amanda Feilding, et al.
Journal of Psychopharmacology (Oxford, England)|May 1, 2023
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depressionBrandon Weiss, David Erritzoe, Bruna Giribaldi, et al.
Acta Poloniae Pharmaceutica|April 6, 2006
Preparation, structure and affinity for imidazoline I2 receptors and alpha2-adrenoceptors of 1-[(4,5-dihydroimidazolidin-2-yl)imino]indan-2-olsAnita Kornicka, Franciszek Saczewski, Robin J Tyacke, et al.
Journal of Psychopharmacology (Oxford, England)|March 15, 2006
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteersJayne E Bailey, Adrian Kendrick, Alison Diaper, et al.
Journal of Psychopharmacology (Oxford, England)|February 2, 2022
Adverse effects of psychedelics: From anecdotes and misinformation to systematic scienceAnne K Schlag, Jacob Aday, Iram Salam, et al.
Psychopharmacology|January 17, 2007
A translational, caffeine-induced model of onset insomnia in rats and healthy volunteersLouise M Paterson, Sue J Wilson, David J Nutt, et al.
Psychiatry Research|May 22, 2003
Increased sympathetic response to standing in panic disorderNick J Coupland, Susan J Wilson, John P Potokar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 19, 2013
A translational rodent assay of affective biases in depression and antidepressant therapySarah A Stuart, Paul Butler, Marcus R Munafò, et al.
Pageof 39